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Infections in Stem Ce[[ Transp[ant Recipients $29 
Conclusions: The tiketihood of being CMV seroposi- 
tire is higher in femates and order individuats. The 
risk has been decreasing over time both SCT pa- 
tients and their donors. The tiketihoods vary greatty 
between different countries. 
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Infectious Complications in Patients Treated for 
Hematological Malignancies 
C. Orasch J6rg*, M. Weisser, A. Widmer, 
M. Battegay, S. Christen, D. Helm, A. Gratwoht, 
U. Ftuckiger. Division of Infectious Diseases Et 
Hospital Epidemiology, University Hospital Basel, 
Switzerland 
Background: Infections are a reading cause of 
comptications in patients treated with high-dose 
chemotherapy and/or hematopoietic stem cett 
transptantation (HSCT) for hematotogicat matig- 
nancies. 
Methods: In a prospective observationat cohort 
study we recorded art btoodstream infections (BSI) 
and art new putmonary infittrates in patients hospi- 
tatized at the Hematotogic Reverse Isotation Unit of 
the University Hospitat Base[ from Jury 2003 untit 
June 2005. Putmonary infittrates were separated 
into bacteriat or fungat pneumonia according to 
microbiotogicat and radiotogicat findings. Invasive 
aspergillosis (IA) was ctassified as proven, proba- 
bte or possibte according to EORTC/MSG consensus 
definitions. 
Results: From Jury 2003 to June 2005, 160 pa- 
tients with 249 episodes of hospitatization were 
included. 91 (36%) episodes occurred during at- 
togeneic HSCT, 40 (16%) to autotogous HSCT and 
118 (47%) to induction/consotidation chemothera- 
pies. We noted 44 (18%) episodes of BSI (incidence 
13.8/1000 days of neutropenia), 53 (21%) episodes 
of pneumonia (incidence 17.3/1000 days of neu- 
tropenia) and 35 (14%) episodes of IA (26 possibte, 
5 probabte, 4 proven). IA occurred in 15/95 (16.5%) 
attogeneic HSCTs, in 16/118 (16%) chemotherapies 
and in onty 1/40 (2.6%) episodes of autotogous 
HSCT. The highest incidence of infectious compti- 
cations was seen in patients undergoing attogeneic 
HSCT (59/91, 65%), fottowed by patients receiving 
high-dose chemotherapies (58/118, 49%) and [ow- 
est after autotogous HSCT (12/40, 30%). Overatt 
in-hospitat mortatity was 13%; 12% in attogeneic 
HSCT, 8% in chemotherapies and 0% in autotogous 
HSCT. 
Conclusion: The incidence of BSI was tower 
than reported in the titerature, possibty retated 
to the routine use of chtorhexidine-suffadiazine- 
coated catheters. The incidence of pneumonia was 
higher probabty because of the regutarty performed 
CT scans. However, the IA rate was comparabte to 
the titerature. 
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Long-Term Suppressive Acyclovir (ACV) Use 
Reduces Varicella Zoster (VZV) Diseases 
and Emergence of ACV-Resistant Herpes 
Simplex Viruses (HSV) After Stem Cell 
Transplantation (HCT) 
V. Erard*, A. Ward, W. Leisenring, C. Vartey, 
J. Heuget, L. Corey, M. Boeckh. Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA 
Background: One-yr ACV use effectivety reduces 
VZV disease at one yr after attogeneic HCT, but VZV 
disease continues to occur in patients on persistent 
immune suppression (Boeckh et at. Brood, 2006). 
Objectives: To determine the efficacy of two tong- 
term suppressive ACV regimens sequentiatty intro- 
duced at the Fred Hutchinson Cancer Research 
Center (FHCRC) in preventing VZV disease after 
attogeneic HCT. To evatuate the impact of tong- 
term suppressive ACV use on ACV-resistant HSV 
disease. 
Methods: Three cohorts of VZV seropositive T 
cett reptete attogeneic HCT recipients were ex- 
amined: cohort 1 (no ACV; before 1999, N=722), 
cohort 2 (ACV 800 mg or VACV 500 mg BID for 1 yr; 
1999-2002; N= 851 ), and cohort 3 (ACV/VACV as in 
cohort 2 ptus extended use in patients on contin- 
ued immunosuppressive drugs at 1 yr; 2002-2003, 
N = 402). The crude incidence rates of VZV disease 
in the 3 cohorts were catcutated at 1 yr and at 2yrs 
after HCT. Rate ratios (RR) were estimated by the 
Mantet-Haenszet person-time chi-square statistic. 
The probabitity of first VZV disease was evatuated 
using cumutative incidence estimates. The tog-rank 
test was used to assess the equatity of CI curves. In- 
cidence of taboratory proven HSV and ACV-resistant 
HSV disease was compared between the groups us- 
ing the fisher exact test. P vatues were two-sided. 
Results: At 1 yr after HCT, VZV disease decreased 
from 35.2 per 100 person-yrs in cohort 1 to 4.5 in 
cohort 2 and 1.4 in cohort 3; by two yrs after HCT, 
VZV disease decreased from 28 per 100 person- 
yrs in cohort 1 to 7.3 in cohort 2 and 3.6 in 
cohort 3. The incidence rate ratio (RR) comparing 
cohort 2 and cohort 3 to cohort 1 was 0.26 (95%CI 
0.20-0.34, p<0.001) and 0.12 (95%CI 0.07-0.21, 
p < 0.001), respectivety. RR comparing cohort 3 to 
cohort 2 was 0.48 (95%CI 0.28-0.84, p=0.008). 
The fraction of cases of VZV disease prevented 
exctusivety by ACV in cohort 2 and in cohort 3 was 
73% and 87% respectivety. One-yr (cohort 2) and 
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>l-yr (cohort 3) ACV prophytaxis prevented 44% 
and 35%, respectivety, of art potentiat cases of VZV 
disease. The 2-yr probabitity of 1st episode of VZV 
disease was 26%, 8% and 4% in cohort 1, 2 and 3 
respectivety (cohort 28:3 vs cohort 1, p <0.001, 
cohort 2 vs cohort 3, p=0.02). Art VZV cases re- 
sponded to treatment with ACV or VACV. During 
the study period, 10 episodes of ACV-resistant HSV 
were documented in cohort 1 and 2 episodes in 
cohorts 2 (p = 0.002). 
Conclusions: Long-term suppressive ACV prophy- 
taxis significantty reduces the incidence of VZV 
disease during the 1st yr after HCT with no de- 
tectabte rebound disease after discontinuation of 
prophytaxis. 
Continuation of ACV beyond 1 yr in patients on 
immunosuppressive drugs may further decrease 
the risk of VZV disease. Suppressive acyctovir use 
strongty reduces the risk of ACV-resistant HSV in- 
fection. 
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A Prospective Study of Parvovirus B19 
Infections in Pediatric Solid-organ and Bone 
Marrow Transplant Recipients and Pediatric 
Solid Tumor Patients: Preliminary Results 
D. Muttu, A. Kupesiz, D. Cotak, V. Hazar, G. Ongut, 
G. Tezcan, G. Aydin, A. Yesitipek, M. Guttekin*. 
University School o[ Medicine, 07070 Antalya, 
Turkey 
Background: In immunotogicatty normat hosts, par- 
vovirus B19 virus can cause, acute, generatty serf- 
timiting diseases, whereas in immunocompromised 
hosts, the infection can persist, reading to chronic 
anemia, red cett aptasia, thrombocytopenia, neu- 
tropenia and even pancytopenia. Chitdren are 
probabty at highest risk, since they may not yet 
have encountered the infection in rife and thus tack 
immunity. The ctinicat and hemathotogicat picture 
of a parvovirus B19 infection may mimic a teukemic 
retapse or therapy-induced cytopenia. 
Objectives: The aim of this study is; to investigate 
parvovirus B19 infections in pediatric sotid-organ 
and bone marrow transptant recipients and sotid 
tumor patients by serotogicat and motecutar meth- 
ods and investigate their ctinicat benefit during one 
year period. 
Methods: One hundred and seven ptasma samptes 
from 28 chitdren with sotid tumor or who have 
sotid-organ or bone marrow transptantation in Ak- 
deniz University Medicat Facutty, Antatya, Turkey, 
were corrected on a monthty basis for a year. Mi- 
cro ELISA based method were used to detect Par- 
vovirus B19 IgM (Novum Diagnostica, Dietzenbach, 
Germany) and IgG (Focus Diagnostics, Catifornia, 
USA) antibodies. Parvovirus B19 DNA was detected 
with LightCycter-parvovirus B19 quantification kit 
(Roche, Mannheim, Germany). An in-house PCR 
method was atso used for Parvovirus B19 DNA de- 
tection. 
Results: Sixteen patients were positive for Par- 
vovirus B19 IgG antibodies. One patient was pos- 
itive for Parvovirus IgG and IgM antibodies. For an- 
other patient onty Parvovirus IgM antibodies were 
positive. Incoconsistent parvovirus B19 IgG test re- 
sutts were observed in consecutive ptasma samptes 
from same patients. Parvovirus B19 DNA was posi- 
tive in first samptes of five patients by LightCycter- 
parvovirus B19 quantification kit, ranging between 
250-1124 copies/mL. Fottowing samptes of these 
patients were negative. Parvovirus B19 DNA was 
negative in art samptes by in-house PCR. The pa- 
tient who has 1124copies/mL of Parvovirus B19 
DNA, had significantty reduced hemogtobin and 
hematocrit resutts and fever was noted for the 
sampting time. For the other four patients, ctinicat 
and taboratory findings were not suggestive for an 
active Parvovirus B19 infection. 
Conclusion: Sensitive rear-time PCR assays are 
mandatory for diagnosing active Parvovirus B19 in- 
fections in sotid organ and bone marrow transptant 
recipients and patients with sotid tumor especiatty 
in the chitdhood. Serotogicat methods are inade- 
quate and insensitive for this group of patients. 
55 
High Incidence of Clostridium di[ficile-associated 
Diarrhea (CDAD) in Hematopoietic Stem Cell 
Transplant (HSCT) Patients during 2005 
K.J. Vigit*, T. Sheppard, J.A. Adachi, R. det Busto. 
Department o[ Internal Medicine, Henry Ford 
Hospital, Detroit, MI, USA 
Background: The incidence and severity of CDAD 
has increased in recent years atong with the pres- 
ence of a more virutent strain. However, there are 
no recent studies rooking at the characteristics of
this infection in HSCT recipients, a poputation at 
increased risk. 
Objectives: To evatuate the incidence and charac- 
teristics of CDAD and the associated risk factors of 
this infection in patients who underwent attogeneic 
and autotogous HSCT at Henry Ford Hlospitat during 
2005. 
Methods: We performed a retrospective, un- 
matched, case-controt study from January to De- 
cember 2005. Inctusion criteria were HSCT patients 
with CDAD diagnosed by identification of C. di[- 
ficile toxin A or B in stoot by ELISA and ctinicat 
